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The contribution of acidosis to renal osteodystrophy
Principal discussant: DAVID A. BUSHINSKY
Strong Memorial Hospital, University of Rochester, Rochester, New York
A 5-year-old boy was admitted to the hospital 19 years ago for repair of
primary hypospadias. The serum creatinine was 1.2 mg/dl; the BUN, 33
mg/dl; and the bicarbonate concentration, 23 mEq/liter. The creatinine
clearance, determined from a 24-hour urine collection, was 75 mI/mm/I .73
m2. An intravenous pyelogram demonstrated a faint nephrogram on the
right and no nephrogram on the left. Renal function was markedly
diminished bilaterally with dysplastic pelvicalyceal systems and renal
dysplasia affecting the left renal parenchyma more than the right. A
voiding cystourethrogram demonstrated a distended and irregular bladder
with massive bilateral reflux, distended calyces and pelves, and tortuous,
dilated ureters. After voiding and standing, most of the contrast medium
was drained from the upper collecting system; however, the bladder
contained 500 ml of residual urine. A urologist advised against surgery
because the patient had never had a urinary tract infection.
Over the next several years, the patient's renal function progressively
declined. Thirteen years ago, the serum creatinine was 3.9 mgldl; phos-
phate, 5.5 mgldl; calcium, 8.8 mg/dl; and bicarbonate, 22 mEq/liter.
Aluminum hydroxide was administered, as was vitamin D. Six months
later, the serum creatinine was 4.9 mgldl; phosphate, 6.1 mg/dl; calcium,
8.6 mg/dl; and bicarbonate, 20 mEq/liter. Oral sodium bicarbonate was
given and the aluminum hydroxide was increased. In spite of marked
increases in oral aluminum hydroxide and sodium bicarbonate, the serum
phosphate level ranged from 5.2 to 7.4 mgldl (mean, 6.2 mg/dl over 2
years) and the bicarbonate ranged from 16 to 23 mEq/liter (mean, 20.7
mEq/liter) as the serum creatinine increased to 9.8 mg/dl over the next 18
months.
Approximately ii years ago, peritoneal dialysis was begun. The patient
was evaulated for transplantation at 3 major university centers, but each
required that bilateral nephrectomy be performed prior to transplanta-
tion; the patient and his family refused. Nine years ago, the patient's mode
The Nephrology Forum is funded in part by grants from Amgen,
Incorporated; Merck & Ca, Incorporated; Marion Merrell Dow, Incorpo-
rated; Dialysis Clinic, Incorporated; and R & D Laboratories.
© 1995 by the International Society of Nephrology
of dialysis therapy was converted to hemodialysis because of several
episodes of peritonitis. He was often noncompliant with his diet and
medications, and he missed many dialysis sessions. While on hemodialysis,
the serum phosphate ranged from 4.8 to 7.8 mg/dl (mean, 6.4 mg/dl), the
calcium varied from 9.8 to 10.5 mgldl (mean, 10.2 mg/dl), and the
bicarbonate ranged from 15.8 to 22.6 mEq/liter (mean, 19.4 mEq/liter).
Four years ago, radiographic examination of the wrists and knees revealed
changes typical of secondary hyperparathyroidism.
The patient sustained a right femoral neck fracture after a minor fall 2.5
years ago. Because of the unstable pattern of the fracture, he was fitted
with a right porous coated bipolar hemi-arthroplasty. Pathologic exami-
nation of the femoral head revealed markedly increased osteoclastic
activity with dissecting osteitis and extensive periarticular fibrosis. Tissue
from the region of the femoral neck showed extensive fibrosis in the
marrow space with marked increased osteoclastic and osteoblastic activity
consistent with renal osteodystrophy most likely resulting from severe
secondary hyperparathyroidism. Osteomalacia could not be excluded on
the decalcified preparation, however.
Twenty-seven months ago, the serum PTH was 1283 pg/mI (normal,
0—55 pg/ml) and on repeated testing, 1121 pg/mI. The serum calcium was
10.3 mg/dl; phosphate, 5.1 mgldl; and bicarbonate, 19.0 mEq/liter. A
thyroid/parathyroid ultrasound examination revealed bilateral masses
(approximately 1.5 X 1.4 x 2.0 cm) in the upper lobes of the thyroid.
Shortly thereafter, the patient underwent a total parathyroidectomy with
implantation of parthyroid fragments into the right forearm. Surgery
disclosed 4 hyperplastic parathyroid glands later determined to weigh as
much as 4 g each. Alter a 2-month period of asymptomatic hypocalcemia,
his serum calcium returned to the normal range.
Two years ago, the patient underwent a living-related renal transplant
without pretranspiant nephrectomy. Currently he is doing well with a
serum creatinine of 1.5 mg/dl.
Discussion
DR. DAVID A. BUSHINSKY (Chief Nephrology Unit, Strong Me-
morial Hospital, and Professor of Medicine and Physiology, Univer-
sity of Rochester School of Medicine and Dentistry, Rochester, New
York): This unfortunate young man developed progressive renal
insufficiency and ultimately total renal failure. His saga of almost
tvo decades could be the focus for a variety of discussions, such as
the efficacy of urologic repair of vesicoureteral reflux, the need for
pretranspiant nephrectomy in patients with refiux, indications for
and timing of parathyroidectomy, post-parathyroidectomy hy-
pocalcemia, etc. I plan, however, to concentrate on a single
problem, one that has received relatively little recognition in the
recent past—the contribution of metabolic acidosis to renal
osteodystrophy. This problem was never addressed formally as an
important issue in the management of this patient, despite the fact
that he was persistently, albeit modestly, hypobicarbonatemic and
almost certainly acidemic for nearly 20 years.
To examine how acidemia can contribute to renal osteodystro-
phy, I will first review the mineral and cellular components of
bone and the calcium, phosphorus, parathyroid hormone (PTH),
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and vitamin D axis. I will consider the types of renal osteodystro-
phy and the pathogenesis of each and review in-vivo and in-vitro
observations that define how bone responds to a fall in pH and
bicarbonate. I will discuss the evidence in support of, and in
opposition to, a role for acidosis in renal osteodystrophy and, last,
the need for correction of acidosis in patients with renal insuffi-
ciency and those undergoing dialysis.
Bone and mineral metabolism
Bone. The skeleton not only maintains the physical structure of
mammals but has a critical role in maintaining ionic homeostasis
[1—31. Bone contains both mineral and organic phases. The
mineral phase consists of highly substituted hydroxyapatite
(Ca10(P04)60H2) crystals. The cations sodium, potassium, and
magnesium can substitute for calcium, and the anion carbonate
can substitute for a phosphate or a hydroxyl [4—8]. Over 99% of
body calcium and approximately 80% of body carbonate are
contained within the mineral phases of bone [9—11].
The organic portion of bone contains unmineralized matrix and
bone cells. The unmineralized matrix consists primarily of type-i
collagen and several other proteins such as osteocalcin and
osteonectin. There are three types of bone cells: osteoblasts,
osteocytes, and osteoclasts. The osteoblast synthesizes the organic
matrix, the osteoid, and has receptors for PTH and 1,25(OH)2D3
[12, 13]. An osteoblast that ceases to secrete matrix and becomes
embedded in mineral is termed an osteocyte. The osteoclast
resorbs bone mineral through vectorial H secretion into the
microenvironment between the cell and the bone mineral [14—161
(Fig. 1). This process is driven by an electrogenic H ATPase.
Chloride enters this microenvironment through a chloride chan-
nel. The intracellular pH of the osteoclast remains relatively
constant through egress of HCO3 — in exchange for extracellular
C1 [171. The communication and coordination between osteo-
blastic formation and osteoclastic resorption result in a turnover
of 10% to 15% of the skeleton each year. This normal bone
turnover might be necessary to repair microfractures and prevent
them from coalescing into clinically significant fractures.
Calcium, phosphorus, PTH, and the vitamin D axis. The synthesis
of 1,25(OH)2D3 is governed by the la-hydroxylase located in the
mitochondria of the proximal tubule cells [1, 2, 18]. The most
potent stimulator of intestinal calcium and phosphorus absorp-
tion, 1,25(OH)2D3 also suppresses the secretion of PTH (Fig. 2).
1,25(OH)2D3 can stimulate bone resorption and/or formation,
depending on the ionic environment; its secretion is controlled by
PTH, calcium, and phosphorus. PTH mobilizes bone calcium by
increasing osteoclastic bone resorption and by increasing the
secretion of 1,25(OH)2D3. PTH, regulated by calcium and
1,25(OH)2D3, is phosphaturic and hypocalciuric. Elevation in the
concentrations of calcium and phosphorus, and especially of their
product, can not only increase bone mineralization but can induce
soft-tissue calcification as well. An increase in the concentration
of hydrogen ions in the microenvironment between osteoclasts
and bone mineral can stimulate direct physicochemical bone
dissolution as well as cell-mediated bone resorption.
Renal failure directly disrupts this complex homeostatic mech-
anism on a number of fronts, including causing phosphate and
hydrogen ion retention, and decreased 1,25(OH)2D3 production
with resultant hypocalcemia and elevated serum PTH levels.
These ionic and hormonal perturbations, in turn, alter bone
accretion, physicochemical dissolution, and cell-mediated resorp-
tion and lead to disruption of the composition and structure of the
bone.
Renal osteodystrophy
Two principal types of bone disorders are observed in patients
with end-stage renal disease: a high-turnover disorder character-
ized by osteitis fibrosa, and a low-turnover state initially charac-
terized by osteomalacia and more recently by adynamic or aplastic
bone disease [19—21]. In osteitis fibrosa, the number and size of
the osteoclasts are increased, as are the number and depth of the
osteoclastic resorption lacunae. Collagen deposition is less or-
dered, and the rate of bone turnover is markedly increased.
Osteomalacia results from defective bone mineralization. In os-
teomalacia the rate of mineralization is slower than that of
collagen synthesis, and excessive accumulation of unmineralized
osteoid and widened osteoid seams result. In aplastic or adynamic
uremic osteodystrophy, a similar marked reduction in the rates of
mineralization and collagen synthesis results in osteoid seams of
normal width. While these disorders often are discussed as if they
were distinct, they overlap enough to suggest a continuous
distribution between extremes at either end of the spectrum.
High-turnover uremic osteodystrophy. The approximately 25
mmoles of phosphate absorbed by the intestine each day must be
excreted quantitatively by renal mechanisms to maintain neutral
balance of total-body phosphate. Any decrease in renal excretion
that is not balanced by a decrease in intestinal absorption must
lead to an increase in the concentration of extracellular fluid
phosphate or to an increase in bone or soft-tissue phosphate
deposition or to both. Renal insufficiency is accompanied by a
decrease in urinary phosphorus excretion with resultant hyper-
phosphatemia [22, 23] (Fig. 3); a strong inverse correlation exists
between creatinine clearance and serum phosphate levels [22].
With a decline in renal function, 1,25(OH)2D3 falls, especially
when the creatinine clearance falls below 50 mI/mm [19, 24]. The
decrease in 1,25(OH)2D3 levels is due in part to the inhibitory
activity of the elevated serum phosphate concentration on in-
hydroxylase [25] and in part to the decrease in the number of
functional proximal tubule cells. The decrease in i,25(OH)2D3
levels causes a lowering of biologically active ionized calcium due,
in most part, to a decrease in 1,25(OH)2D3-stimulated intestinal
calcium absorption [26, 27]. Soft-tissue calcium deposition also
Bone
Fig. 1. Schematic diagram of an osteoclast.
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1 ,25(OH)2D3
Fig. 2. Schematic diagram of the regulation of
calcium, phosphorus, hydrogen ions, parathyroid
hormone (PTH), and 1,25-dihydroxyvitamin D3
(1,25(OH)2D3) in relation to bone. Solid arrows
indicate upregulation or bone formation and
dashed arrows indicate downregulation or bone
dissolution. (From Ref. 1.)
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might contribute to the decline in serum ionized calcium [281. The
fall in ionized calcium stimulates the synthesis and release of PTH
[29].
Parathyroid cells have specific receptors for 1,25(OH)2D3 [30—
32] that, when occupied, suppress PTH gene expression and the
secretion of PTH [33—38]. In addition, renal failure is accompa-
nied by decreased binding of 1,25(OH)2D3 to the parathyroid cell
receptors [39]. Thus, during renal failure the combination of
decreased serum levels of 1,25(OH)2D3 and decreased binding of
1,25(OH)2D3 to the parathyroid cells markedly increases PTH
secretion at all levels of ionized calcium. This so-called "altered
set point" for PTH secretion can be reversed by the administra-
tion of 1,25(OH)2D3 [40, 41], by noncalcemic analogues of
vitamin D (such as 22-oxocalcitriol) [42], and perhaps by retinoic
P
I
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I
——I
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H
/ Fig. 3. Schematic diagram of the mechanism
leading to increased bone turnover during renal
failure.
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acid [43]. Parathyroid hormone is degraded principally in the liver
and the kidney into carboxy-terminal fragments, which are catab-
olized by the kidney [44—46J. With renal failure, PTH and
carboxy-terminal fragments accumulate in the serum; some of the
latter are also biologically active [47].
Thus declining renal function brings a progressive increase in
the serum PTH level. This increase in PTH increases urinary
phosphate excretion, thus stabilizing the level of serum phos-
phate. However, a prQgressive decline in renal function leads to a
continuing increase in serum phosphate and thus PTH. Although
the elevated PTH level tends to stabilize the serum phosphate
level, it adversely affects the bone mineral by stimulating osteo-
blastic and then osteoclastic activity. As I will discuss later,
acidosis has been shown to independently stimulate osteoclastic
bone resorption and physicochemical bone dissolution.
Low-turnover uremic osteodystrophy. Originally thought to result
from vitamin D deficiency, osteomalacia has been closely associ-
ated with aluminum toxicity. Aluminum was first identified as a
presumed cause of dialysis dementia in dialysis patients [48, 49],
and shortly thereafter aluminum deposition in bone was associ-
ated with osteomalacia [50, 51]. The sources of aluminum were
phosphate binders and the water used in making dialysate [52],
Aluminum is no longer present as a contaminant in dialysate, but
it still is widely utilized as a phosphate binder. Approximately
one-third of dialysis and chronic renal failure patients ingest at
least some aluminum. Aluminum deposits within the mineraliza-
tion front [53], the surface where the osteoid meets the mineral-
ized bone, and adversely affects mineralization [54]. In addition,
aluminum reduces the number and activity of osteoblasts [55]. In
in-vitro experiments, our laboratory has shown that aluminum
decreases osteoblastic bone formation [56] and increases oste-
oclastic bone resorption [57].
Aplastic renal osteodystrophy occurs in many patients who have
no evidence of excess aluminum accumulation [58, 59]. These
patients have relatively low levels of PTH. The disorder is
associated with the use of supraphysiologic calcium concentra-
tions in peritoneal dialysate and the use of oral calcium carbonate;
these sources of exogenous calcium might lower serum PTH to
levels that are inadequate for maintaining normal bone turnover
[58]. As I will discuss, acidosis independently inhibits osteoblastic
collagen deposition and bone nodule formation.
Effects of acid on bone
On a daily basis, the metabolism of dietary protein generates
approximately 1 mEq/kg of hydrogen ions in adults. The hydrogen
ions must be excreted, primarily by renal mechanisms, if neutral
acid-base balance is to be maintained [60]. In the presence of
renal insufficiency, humans cannot excrete this daily endogenous
acid production. To moderate a significant reduction in systemic
pH, soft tissue and bone buffer the excess retained hydrogen ions.
The additional hydrogen ions induce bone mineral to release
calcium [61—64] by physicochemical as well as by cell-mediated
mechanisms [3, 65]. Progressive renal dysfunction (prior to the
induction of renal replacement therapy) is accompanied by con-
tinued endogenous production of acid and inadequate net acid
excretion, resulting in sustained acidemia. Hernodialysis, whether
utilizing a bath containing bicarbonate or a bicarbonate precursor,
increases the concentration of serum bicarbonate and blood pH,
both of which will begin to fall again shortly after the dialysis
procedure [66]. Patients dialyzed against bicarbonate, compared
with patients dialyzed against acetate, appear to have a higher
predialysis concentration of serum bicarbonate [67, 68]; however,
such patients remain hypobicarbonatemic [69]. Peritoneal dialysis
maintains a more stable bicarbonate and pH [70]. In both forms of
renal replacement therapy, however, both predialysis bicarbonate
and pH are generally at lower-than-normal physiologic levels,
indicative of sustained metabolic acidosis [71, 72].
Several questions must be addressed. What is the effect on bone
of (1) the universal chronic acidemia that occurs prior to renal
replacment therapy, (2) the chronic acidemia observed in patients
undergoing dialysis, and (3) the acute worsening of acidemia
observed in the intervals between dialysis sessions? The indepen-
dent effect of acidosis on human bone during uremia is difficult to
determine in vivo, as bone is a very large organ in which changes
in its mineral phase occur slowly. But we can utilize in-vitro
studies to guide us in understanding the relevant physiology [1—3,
60, 65]. 1 will now consider the response of bone to acute acidosis
and then to chronic acidosis.
Acute acidosis
Calcium release. When mineral acid is infused into nephrecto-
mized animals, serum calcium rapidly increases [73]. As bone
contains over 99% of total body calcium [10, 11], this finding
implies mineral dissolution. Using cultured neonatal mouse cal-
variae (the frontal and parietal bones of the skull), we determined
that a physiologic decrease in medium pH, produced by a
decrease in bicarbonate concentration of 3 hours duration, causes
bone mineral dissolution [74, 75]. Calcium is released from the
bone mineral into physiologically acidic medium; no change
occurs in the medium calcium when bone is cultured in neutral
medium; and an influx of calcium occurs into bones cultured in
alkaline medium [74, 75].
The mechanism by which hydrogen ions induce the release of
bone calcium during this short time period could be direct
physicochemical calcium dissolution or stimulation of osteoclastic
bone resorption. The role of cellular activity in proton-mediated
bone resorption was determined in calvariae cultured with agents
that stimulate or suppress osteoclastic bone resorption but do not
affect the bone mineral directly [75]. Over a 3-hour time period,
osteoclastic activity accounted for a constant, pH-independent
effiux of calcium from the mineral [75]. Thus the proton-mediated
release of bone calcium over this time period appears to be due to
alterations in the physicochemical factors that govern the depo-
sition and dissolution of the bone mineral and not to alterations in
osteoclastic bone resorptive activity.
To confirm that hydrogen ions could alter physicochemical
forces and promote dissolution of the bone mineral, we exposed
synthetic carbonated apatite disks to physiologically acid medium
[761. The synthetic carbonated apatite disks are an accurate,
cell-free model of bone mineral that can be utilized to study pure
physicochemical mineral dissolution. Calcium is released from
such disks in response to a physiologic decrement in pH. This
finding supports the hypothesis that excess hydrogen ions induce
physicochemical calcium release from bone [76].
The type of bone mineral in equilibrium with the medium, and
thus influenced by the physicochemical forces to release calcium,
might be carbonate or phosphate in association with calcium, To
determine which, we cultured calvariae in medium in which the
driving forces for crystallization with respect to the solid phase of
the bone mineral were altered by changing the medium pH, and
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Fig. 4. Net calcium flux (nmol/bonel3 hr) as a function of initial medium[HC03] in cultured neonatal mouse calvariae. The SE for all mean values
shown are less than the size of the corresponding symbol. Ctl, calvariae
cultured in unaltered medium; Met, calvariae cultured in medium acidi-
fled to —7.10 by the addition of HCI; Resp, calvariae cultured in medium
acidified to —7.10 by increasing the incubator (and thus the medium)
partial pressure of CO2 (PCO2); C-Met, medium [HC03] lowered as in
Met, but initial pH maintained at —7.43 by lowering the medium PCO2;
C-Resp, medium PCO2 increased as in Resp, but initial pH maintained at
—7.43 by increasing the medium [HC031. Solid line depicts pH 7.4;
dashed line represents pH of 7.1. (From Ref. 81.)
calcium and phosphorus levels [77]. We found bone formation in
the presence of a medium supersaturated with respect to calcium
and carbonate but not to calcium and phosphate; there was no
change in the bone mineral in the presence of a saturated
medium, and there was bone dissolution in the presence of an
undersaturated medium. Thus bone carbonate, but not apatite,
appears to be in equilibrium with the culture medium and is
solubilized during a reduction in medium pH, leading to a release
of calcium. Other studies indicate that the bone carbonate is
present in the form of carbonated apatite [78—80].
Further support for the role of carbonate in proton-mediated
bone mineral dissolution comes from studies in which calcium
effiux from bone was demonstrated to depend on the medium
bicarbonate concentration [81]. At a constant pH, whether phys-
iologically neutral or acidic, the lower the bicarbonate concentra-
tion, the greater the calcium efflux [811 (Fig. 4). Thus, substantial
evidence indicates that bone responds within 3 hours to a decre-
ment in pH that is well within the range commonly observed
during progressive renal insufficiency, and in many dialysis pa-
tients, especially in the interval between dialysis treatments.
Hydrogen ion buffering. Bone not only responds to acidemia by
increasing calcium effiux, but functions as a hydrogen ion buffer,
thereby helping to restore the pH toward the normal range. Forty
years ago, Swan and Pitts demonstrated that approximately 60%
of the hydrogen ions administered by the infusion of an acute acid
load are buffered outside the extracellular fluid (ECF) by soft
tissues and bone [821. The in-vivo evidence that bone buffers
respond to acute acid loads derives principally from the loss of
bone sodium [83—86] and from the depletion of bone carbonate in
response to acute acidosis [77, 87, 88]. Sodium loss from bone
suggests the occurrence of proton for sodium exchange, and
carbonate loss suggests the consumption of this buffer by protons.
The in-vitro evidence is derived from proton flux studies into bone
[74, 77, 83, 89, 90] and from microprobe evidence for a depletion
of bone sodium during acidosis [83, 84].
Bone is a reservoir for sodium and potassium, and its surface
has fixed negative sites that normally complex with sodium,
potassium, and hydrogen ions; the sodium appears to exchange
freely with that in the surrounding fluid [10, 11]. A decrease in
systemic pH allows hydrogen ions to displace sodium and potas-
sium from the mineral surface, and results in an egress of these
ions and in a contribution to the buffering of systemic acidity.
Several experimental studies support this sequence of events.
Four hours after the intraperitoneal injection of ammonium
chloride into rats, bone sodium falls by approximately 28% [85];
moreover, rat bones lose approximately 7 mEqlkg of exchange-
able bone sodium after 5 hours of metabolic acidosis [86].
In-vitro studies documenting the loss of bone sodium provide
evidence that bone functions as a hydrogen ion buffer. When
neonatal mouse calvariae are cultured in medium acidified by a
decrease in bicarbonate concentration, a net influx of hydrogen
ions into the bone occurs, and the hydrogen ion concentration of
the medium decreases. These findings indicate that the hydrogen
ions are buffered by bone [74, 77, 83, 89, 90]. Examination of
calvariae with a high-resolution scanning ion microprobe demon-
strates that the surface of bone is rich in sodium and potassium
relative to calcium [83, 84, 91—94]. Incubation of calvariae in a
physiologically acidic medium results in a loss of surface sodium
and potassium relative to calcium in conjunction with proton
buffering. Thus sodium-for-proton and potassium-for-proton ex-
change occurs on the bone surface [83]. Microprobe analysis of
the bone surface during inhibition of osteoclastic function by
calcitonin indicates that physicochemical hydrogen ion buffering
by bone causes release of calcium and sodium [84].
Bone contains approximately 80% of the total "carbon dioxide"
pooi (that is, CO32, HC03, and C02) in the body [9]. Approx-
imately two-thirds of the carbon dioxide in bone is in the form of
carbonate (C032) complexed with calcium, sodium, and other
cations, and is located in the lattice of the bone crystals, a site that
is relatively inaccessible to the systemic circulation. The other
one-third consists of bicarbonate (HC03), which is located in
the hydration shell of hydroxyapatite, a site that is readily
available to the systemic circulation.
Acute metabolic acidosis decreases bone total carbon dioxide.
Bettice determined bone carbon dioxide in rats 24 hours after the
initiation of acid loading or the onset of diabetic ketoacidosis [87].
He found that bone total carbon dioxide fell with acidosis and that
the fall was directly proportional to the decline in the extracellular
fluid pH and bicarbonate concentration. The loss of bone carbon
dioxide, presumably from the readily available HC03 pool,
suggests that bone actively participates in buffering the increased
hydrogen ion concentration. A reduction of the medium pH
induces the release of calcium and carbonate from the bone [77].
When neonatal mouse calvariae are cultured in acidic medium (as
a model of metabolic acidosis), a progressive loss of bone
carbonate occurs [88].
Considering the evidence from both the in-vitro and in-vivo
studies, bone appears to be a potent hydrogen ion buffer capable
of maintaining the extracellular fluid pH near the normal physi-
ologic value. The loss of both bone sodium and carbonate suggests
that bone responds to acidosis both by exchanging sodium for
hydrogen and by the dissolution of carbonated apatite.
Parathyroid hormone promotes cell-mediated resorption of
0
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bone mineral. In conjunction with calcium efflux, bone releases
anionic hydrogen ion buffers (for example, phosphate and carbon-
ate), which are bound to calcium on the bone mineral. It has been
suggested that a fundamental role of PTH is to augment extrare-
nal hydrogen ion buffering [95]. However, careful in-vivo studies
by Madias and coworkers fail to support such a role for PTH [96].
Lemann and coworkers induced acidosis in hypoparathyroid and
normal individuals and found no difference in the resulting
bicarbonate concentration, positive acid balance, or degree of
hypercalciuria [62]. In-vitro studies also fail to support the hy-
pothesis that PTH augments the buffering of an acid load. When
calvariae are cultured for 3 hours in a physiologically acid
medium, hydrogen ions are buffered and pH is returned toward
the normal physiologic range [90]. The addition of PTH to the
culture medium decreases the influx of hydrogen ions into the
bone, indicating that PTH actually inhibits the hydrogen ion
buffering of an acidic medium by neonatal bone [90]. Parathyroid
hormone promotes the resorption of bone mineral by stimulating
osteoclasts to secrete acid into the microenvironment between the
resorbing osteoclast and the bone mineral [14—16, 97, 981. Only
when this acid is able to solubilize the bone mineral are calcium
and its accompanying anionic hydrogen ion buffers released. Not
surprisingly, therefore, PTH actually might retard hydrogen ion
buffering by bone before substantial bone resorption and buffer
release occur [90].
During acute metabolic acidosis, a reduction in pH causes both
calcium release and hydrogen ion buffering. Were all buffering the
result of mineral dissolution, the ratio of hydrogen ions buffered
to calcium ions released would be 1-to-i for calcium carbonate,
5-to-3 for apatite, and i-to-i for brushite. However, with cultured
calvariae the ratio was between i6-to-1 and 21-to-i and indicated
that hydrogen ion buffering could not simply be due to mineral
dissolution [741. That calcium and buffer release is only one
component of proton buffering by bone is clearly demonstrated by
microprobe studies indicating substantial sodium and potassium
for proton exchange [83, 841. In addition, phosphate might
substitutefor carbonate within the bone mineral and result in
hydrogen ion buffering without calcium release [99, iOOJ.
Chronic acidosis
Calcium release. In nonuremic humans, chronic metabolic aci-
dosis increases urinary calcium excretion without altering intesti-
nal calcium absorption and thus results in a net loss of body
calcium [63, 101, 102]. The source of this additional urinary
calcium is almost certainly bone, as over 99% of the body calcium
is contained within the bone mineral [10, 11. In a series of studies,
Lemann and coworkers fed normal subjects protein, NH4CI, and
NaHCO1 and measured their urinary calcium excretion [1011.
Protein (which yields acid during metabolism) and NH4C1 mark-
edly increased renal calcium excretion, whereas NaHCO1 de-
creased it. Intestinal calcium absorption did not change apprecia-
bly with any treatment. Balance studies performed on patients
given NH4C1 demonstrated that much of the acid was retained
and that the serum bicarbonate concentration fell [63]. Twelve
days after the conclusion of the NH4CI administration, an average
of 192 mEq of acid had been retained and 185 mEq of calcium
excreted. The equivalence between hydrogen ions retained and
calcium excreted suggested that bone is both a sink for many of
the hydrogen ions buffered in stabilizing plasma bicarbonate, and
the source of the additional urinary calcium.
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Fig. 5. Effect of metabolic and respiratoty acidosis on f3-glucuronidase
activity. Calvariae were incubated in control medium (Ctl, open circle),
medium acidified to pH —7A5 with HC1 (Met, open square) or medium
acidified to pH —7.15 by increasing the partial pressure of CO2 (Resp,
open triangle). Values are means SEM, and the absence of error bars
indicates that the SEM was less than the width of the symbol. 13-glucuron-
idase activity released into the medium was increased with Met but not
with Resp. There was an inverse correlation between the initial medium
pH and j3-glucuronidase activity in Ctl and Met but not in Ctl and Resp.
(From Refs. 107 and 119.)
Chronic metabolic acidosis appears to induce the release of
bone calcium, as does acute metabolic acidosis, by a direct
physicochemical effect of hydrogen ions on the bone mineral; in
addition chronic metabolic acidosis results in increased cell-
mediated bone resorption. Studies of prolonged acidosis in rats
have shown stimulated cell-mediated bone calcium resorption [73,
103]. The administration of acid leads to an increase in serum
calcium concentration that is independent of increased intestinal
calcium absorption and which is diminished by osteoclastic inhi-
bition with colchicine or calcitonin [731. In acidotic rats, bone
formation is decreased at several sites, and cell-mediated bone
resorption is increased in epiphyseal, but not in cortical or
metaphyseal, bone [1031.
Arnett and Dempster studied the effects of alterations in pH on
cell-mediated bone resorption in vitro [104]. They isolated rat
osteoclasts from neonatal bones and cultured them in an acidic
medium on slices of polished bovine femur and found increased
areas of resorption in the acidic, compared to physiologically
neutral, pH medium. Evidence for cell-mediated bone resorption
also was obtained when calvariae were cultured in acidic medium
[105, 1061. Goldhaber and Rabadjija described increased calcium
release from calvariae cultured for one week in acidic medium;
calcium release was suppressed by the osteoclastic inhibitor
calcitonin [105]. Cell-mediated bone calcium resorption was dem-
onstrated after 99 hours of culture in medium made acidic by a
low bicarbonate concentration [106]. In addition, acidic medium
increases osteoclastic and inhibits osteoblastic activity in vitro
[107]. Release of the osteoclastic enzyme /3-glucuronidase was
stimulated (Fig. 5), while osteoblastic collagen synthesis (Fig. 6)
and alkaline phosphatase activity (Fig. 7) were inhibited by a low
bicarbonate, acidic medium [107].
Further evidence that metabolic acidosis inhibits osteoblastic
function was obtained from osteoblasts in culture. Isolated osteo-
blasts cultured for 3 weeks secrete collagen and form actual
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Fig. 6. Effect of metabolic and respiratoly acidosis on percentage of collagen
synthesis. Calvariae were incubated in control medium (Ct!, open circle),
medium acidified to pH —7.10 with HCI (Met, open square), medium
acidified to pH —7.10 by increasing the partial pressure of CO2 (Resp,
open triangle) or in the presence of 10-8 M parathyroid hormone (PTH,
open diamond) for two successive 24-hr incubations. Values are means
SEM, and the absence of error bars indicates that the SEM was less than
the width of the symbol. Compared to Ct!, collagen synthesis decreased
with Met, and it decreased further with PTH; however, no change
occurred with Resp. There was a direct correlation between the initial
medium pH and collagen synthesis in Ctl and Met but not in Ctl and Resp.
(From Refs. 107 and 119.)
nodules of apetitic bone. Decreasing the medium bicarbonate
concentration leads not only to fewer nodules, but to decreased
calcium influx into the nodules [108]. Thus it appears that both
augmentation of cell-mediated bone resorption and inhibition of
cell-mediated bone formation play prominent roles in the hyper-
calciuria of chronic metabolic acidosis [107, 108].
To determine whether acidosis and PTH have additive effects
on calcium release from bone, we cultured calvariae in acidic
medium containing PTH [109]. Acidic medium and PTFI inde-
pendently stimulated calcium release from bone; however, the
combination resulted in greater calcium efflux than did either
alone. Osteoclastic activity, as determined by j3-glucuronidase
release, was increased with both acidosis and PTH but was
increased even further when the two factors were combined.
These in-vitro findings support the in-vivo observation by Beck
and Webster that PTH stimulates proton-mediated calcium re-
lease from bone [110].
Hydrogen ion buffering. As I said, on a daily basis the metabolism
of dietary protein generates nonvolatile acids that must be
quantitatively excreted for the body to maintain neutral systemic
acid-base balance. In patients with substantial renal insufficiency
or renal failure, a decrease in acid excretion leads to unremitting
positive acid balance. If extracellular fluid bicarbonate were the
only hydrogen ion buffer available, it would become progressively
depleted and the concentration of serum bicarbonate, and thus
pH, would fall to levels incompatible with life. However, during
chronic renal failure, extracellular fluid bicarbonate and pH
remain stable, although reduced, for long periods; thus, either
non-bicarbonate buffers must neutralize the retained hydrogen
ions, or acid production must decrease [1, 2, 111, 1121. Acid
production does not appear to diminish in patients with renal
failure; however, such patients excrete only approximately two-
thirds of their daily hydrogen ion production; thus substantial
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Fig. 7. Effect of metabolic and respiratory acidosis on calvarial alkaline
phosphatase. Calvariae were incubated in control medium (Ctl, open
circle), medium acidified to pH —7.15 with HC1 (Met, open square), or
medium acidified to pH —7.15 by increasing the partial pressure of CO2
(Resp, open triangle). Values are means SEM, and the absence of error
bars indicates that the SEM was less than the width of the symbol.
Compared to Cii, there was a decrease in alkaline phosphatase with Met
but no change with Resp. There was a direct correlation between the
initial medium pH and collagen synthesis in Ct! and Met but not in Ctl and
Resp. (From Refs. 107 and 119.)
buffering of the retained hydrogen ions almost certainly occurs
[112]. Because of its mass and potential buffering capacity, bone
was thought to be a likely site for the chronic hydrogen ion
buffering [112]. The idea that bone is involved in hydrogen ion
buffering in chronic renal failure was supported by the observation
that bone calcium and carbonate are reduced significantly in
patients with uremia and that the reduction is proportional to the
duration of the renal disease [113].
Bone appears to buffer hydrogen ions during acid administra-
tion in non-uremic patients as well. When patients with normal
renal function were fed chronic acid loads, they did not excrete
the administered acid quantitatively, yet their serum bicarbonate
concentration stabilized [63]. Because bone is such a large poten-
tial source of buffer in the body, osseous mechanisms were
thought to be responsible for this observation [63]. As is the case
with acute acidosis, the imposition of a chronic acid load appears
to decrease bone carbonate; thus, bone carbonate might be a
physiologic hydrogen ion acceptor [114, 115].
Role of the anion
Most in-vivo and in-vitro studies have utilized HC1 or NH4C1 to
lower the serum bicarbonate concentration to create a model of
metabolic acidosis. The resulting non-anion-gap acidosis mimics
clinical disorders such as renal tubular acidosis or diarrhea;
however, the acidosis seen in uremia is a combination of non-
anion-gap and increased-anion-gap acidosis. The animal study
most closely relevant to the effect of uremic acidosis on bone was
reported by Chan and coworkers [116]. They subjected rats to
partial nephrectomy and gave some of the animals hydrochloric
acid. The fraction of the bone undergoing resorption and the
density of osteoclasts both were increased by uremia and were
increased further by concomitant HCI acidosis; these findings
suggested that HC1 acidosis and uremic acidosis have additive
effects on osteoclastic bone resorption.
In vitro, the anion accompanying the acid in the medium
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appears to be critical in determining the magnitude of the calcium
release and the hydrogen ion buffering by bone. This first became
evident when a clear distinction was discovered between the
effects of metabolic and respiratory acidosis on cultured bone [1,
2, 60, 74—77, 81, 83, 84, 88—91, 106, 107, 117]. During short-term
incubations, the net efflux of calcium is far greater during meta-
bolic acidosis [89]. Respiratory acidosis is not only accompanied
by less unidirectional calcium efflux from bone, but appears to
cause deposition of medium calcium on the bone surface [117].
This finding is consistent with the observation that acidosis affects
the physicochemical driving forces for mineral formation and
dissolution over short time periods [75, 77, 81, 84]. During
metabolic acidosis, the low [HC03] favors the dissolution, while
during respiratory acidosis the increased PCO2 and [HC03]
favor the deposition, of carbonated apatite. Indeed, respiratory
acidosis does not induce hydrogen ion influx into bone in in-vitro
systems [89].
During incubations of longer duration, net cell-mediated cal-
cium effiux from bone occurs during models of metabolic, but not
of respiratory, acidosis [106]. Many investigators have shown that
metabolic acidosis stimulates osteoclastic resorption [103—107,
117, 1181. In a recent study, respiratory acidosis did not appear to
alter osteoclastic /3-glucuronidase release (Fig. 5), osteoblastic
collagen synthesis (Fig. 6), or alkaline phosphatase activity (Fig. 7)
as did metabolic acidosis [107, 119]. Last, respiratory acidosis does
not appreciably alter the surface ion concentration of bone [91].
We have shown in a preliminary study that, whereas hydrochlo-
ric and nitric acids promoted a robust calcium efflux from bone,
isohydric lactic and pyruvic acid did not produce a substantial
calcium efflux [1201. The lack of appreciable calcium release with
these organic acids is reminiscent of the lack of significant cellular
potassium release with organic as compared to mineral acids.
Effect of acidosis on PTH and 1,25(OH)2D3
Although PTH does not appear to augment buffering of an
acute acid load, could acidosis lead to an increase in PTH, and
thus worsen hyperparathyroidism? Acidosis causes calcium to be
displaced from albumin, and this process tends to increase ionized
calcium [1211 and lower PTH secretion; however, acidosis also
increases urine calcium excretion, which tends to reduce serum
calcium levels and increase PTH secretion. Some clinical studies
report a decrease [122, 123], others no change [124], and still
others a modest increase [95, 125] in PTH levels during acidosis.
Coe and colleagues found that any increase in PTH that occurred
was associated with the acidosis-induced hypercalciuria and not
the acidosis itself [125]. Lemann's group noted no increase in the
serum levels of PTH or urinary cAMP in normal subjects fed
ammonium chloride [123, 124]. Thus, the bulk of clinical data
does not support an independent role for acidosis in increasing
PTH.
The effect of acidosis on vitamin D metabolism is a complex
interplay of a number of ions and hormones. An increase in the
conversion of 25(OH)D3 to 1,25(OH)2D3 is a function of in-
creased serum PTH and/or decreased serum calcium or phospho-
rus [62, 126—130]. The level of PTH appears not to be altered in
acidosis, but acidosis is phosphaturic and calciuric [123, 124]. In
the rat, conversion of 25(OH)D3 to 1,25(OH)2D3 is impaired
during metabolic acidosis [1311 and production of 1,25(OH)2D3 in
the isolated perfused kidney obtained from rats with metabolic
acidosis also is impaired [132]. The basal serum levels of PTH and
1,25(OH)2D3 are not altered by acidosis in the rat [126, 133];
however, during acidosis, 1,25(OH)2D3 does not rise in response
to a low-calcium diet [126], except with concomitant phosphate
depletion [103, 134]. Human studies fail to support an appreciable
decline in levels of 1,25(OH)2D3 in acidemic patients [123, 1241,
and 1,25(OH)2D3 rises in response to PTH during acidosis in
humans [1351.
Clinical observations
Evidence for bone involvement in chronic acidosis. The evidence
that bone is affected by normal endogenous acid production was
recently shown by Sebastian and coworkers [1361. They fed 18
postmenopausal women a diet with constant amounts of calcium
and protein, and then almost completely neutralized endogenous
acid production with supplemental potassium bicarbonate. The
administration of alkali reduced urinary calcium and phosphorus
excretion, and the overall calcium balance became less negative or
more positive (Fig. 8). They also noted a reduced urinary excre-
tion of hydroxyproline, a marker of bone breakdown, and an
increased excretion of serum osteocalcin, a marker of osteoblastic
bone formation. These results support a role for daily endogenous
acid production and low-level acid retention in the development
of osteoporosis in postmenopausal women with normal renal
function [136, 137].
The independent effect of acidosis on bone growth was ele-
gantly determined in a classic study by McSherry and Morris of 10
children with renal tubular acidosis [138]. Initially, the growth rate
of 6 of the 10 was severely depressed; their mean height reached
only the 1.4th percentile; of the other 4, 2 were infants, whose
growth rate could not yet be determined, and 2 were not acidemic.
The heights of the patients correlated inversely with the maximal
duration of prior acidosis. With sustained alkali therapy of 4.8 to
14.1 mEqlkg/day, each patient attained and maintained normal
stature, with a mean height in the 37th percentile. Although the
mechanism of the increased growth velocity attained with bicar-
bonate therapy is not clear from this or subsequent studies,
acidosis, either directly or indirectly (through hormonal or ionic
factors), severely inhibits bone growth [138—140]. In a radio-
graphic study, Brenner and coworkers found that 67% of patients
with proximal renal tubular acidosis had skeletal abnormalities;
the children had widened and irregular epiphyseal-metaphyseal
junctions and bowing deformities consistent with rickets, and the
adults had osteopenia [141]. Sixty-three percent of patients with
distal renal tubular acidosis had nephrocalcinosis, nephrolithiasis,
or both.
Clinical evidence that acidosis adversely affects bone in uremia
also is readily available. Goodman and coworkers studied 8
acidemic patients who had a mean fHC03] of 17 mEq/liter due
to renal insufficiency (mean duration, 6 years). The patients had a
mean creatinine clearance of 40 liters/day and a net positive acid
balance of 19 mEq/day [112]. In spite of this acid retention, the
patients' serum [HC03'] remained constant, indicating that bone
likely was buffering the additional acid. When the concentration
of bicarbonate was corrected in 6 of these patients, the positive
acid balance was eliminated in 5. Litzow and coworkers studied 7
patients with stable chronic renal disease who had a mean
creatinine clearance of 17 liters/day and who were acidemic (mean
bicarbonate concentration, 18 mEq/liter) [102]. Each of the
patients was in small but significant positive acid balance of 10
mEq/day and negative calcium balance of —5.3 mEq/day, the
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latter predominantly from fecal loss. When the acidosis was
completely corrected, calcium loss could no longer be detected.
Mora Palma and colleagues studied 200 patients who underwent
bone biopsy during late renal failure, prior to dialysis or trans-
plantation; the degree of acidosis was closely associated with the
biopsy findings [142]. The most severely acidemic patients (bicar-
bonate concentrations of less than 16 mEq/liter) had a predomi-
nance of osteomalacia and osteofibrosis; the less-acidemic pa-
tients (bicarbonate concentration of greater than 20 mEq!liter)
had only osteofibrosis. West and Smith studied 41 patients with
chronic renal disease and observed acidemia in three-fourths of
the 21 severely growth-retarded patients and no acidemia in the
normally growing patients [143].
Bone carbonate is decreased in uremic patients [113, 144, 145].
Pellegrino and Blitz demonstrated that bone carbonate decreased
by one-third in 22 uremic patients studied for 27 months [113].
These same authors with Letteri demonstrated that bone carbon-
ate was significantly lower in 12 dialysis patients who had been
uremic for approximately 6.5 years compared with non-uremic
controls [1441. Finally, Kaye et al found that bone carbonate was
significantly reduced in 11 patients who were uremic for almost 3
years compared with controls [145]. The fall in bone carbonate
with acidosis observed in vivo parallels in-vitro observations [77, 87,
88]. This decrease might represent dissolution of bone carbonate
stores or replacement of bone CO3 by HPO4; the latter would
result in the incorporation of a hydrogen ion into the mineral.
That correction of acidosis can have a beneficial effect on
uremic osteodystrophy has been reported by several investigators.
Bishop and Ledingham [146] and Cochran and Wilkinson [147]
reported that correction of the acidosis in a small number of
uremic patients resulted in a significant rise in bone mineraliza-
tion and a positive trend in calcium balance. In a carefully
executed and analyzed study, Lefebvre and coworkers prospec-
tively examined the effect of correction of acidosis on renal
osteodystrophy in 21 hemodialysis patients studied for 18 months
[69]. Patients were first divided into those with high and low bone
Fig. 8. Effect of potassium bicarbonate
supplementation on calcium and phosphorus
excretion in urine, external calcium and phosphorus
balance, and calcium and phosphorus excretion in
stool in 18 postmenopausal woman. The values
shown at the bottom of the figure are the average
(± SD) potassium bicarbonate-induced changes
from the control period, before supplementation.
(From Ref. 136.)
formation rates; some of each group (a total of 10 patients) were
then dialyzed against a conventional bicarbonate bath of 33 2
mM, resulting in a predialysis [HCO3] of 15.6 1 mM (control),
and others (a total of 11 patients) had 7 to 15 mM of NaHCO3
added to their dialysis bath to bring their predialysis [HC03] to
24 mM (acidosis-corrected). The control patients had an increase
in osteoid and osteoblastic surfaces and an increase in serum PTH
levels. The acidosis-corrected patients had no change in these
parameters (Fig. 9). These findings imply an increase in secondaiy
hyperparathyroidism in the control patients with no change in the
patients whose acidosis was corrected. The subgroups of patients
with low and high bone formation were then evaluated separately.
The patients with high bone formation had a high plasma level of
osteocalcin, which is a marker of osteoblastic function. Correction
of acidosis moderated the increase in osteocalcin compared to
that in the control patients. The patients with a low bone
formation rate had lower osteocalcin levels, and 7 of 10 had
aplastic bone disease. Correction of the acidosis led to an increase
in osteocalcin levels. Thus this study suggests that the optimal
correction of acidosis curtails the progression of hyperparathy-
roidism in patients with high bone turnover and stimulates bone
turnover in patients with low rates of bone formation.
Evidence against bone involvement in chronic acidosis. The role
of acidosis in uremic osteodystrophy had been minimized in a
number of early studies [148—1501. The authors of these early
studies argued that azotemic rickets and osteomalacia were
similar to osteodystrophy caused by vitamin D deficiency and that
treatment with extremely large doses of vitamin D alone cured the
disorder. Those investigators were apparently attempting to find a
single explanation for the bone disease that develops in uremia.
We now know that correction of vitamin D deficiency is necessary
for improvement of uremic osteodystrophy but it is certainly not
sufficient; otherwise, this clinical problem would have ceased to
exist well over two decades ago.
Oh has argued that, despite the role of bone buffers in acute
metabolic acidosis, bone mineral is insufficient in quantity to have
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Fig. 9. Evolution in time of 44—68 PTH plasma level in control (open
circles) and acidosis-corrected (closed circles) patients. Mean SE. There
is a significant increase of the values of 44—68 PTH with time in the
control group but not in the acidosis-corrected group. (From Ref. 69.)
a substantial effect on stabilizing serum bicarbonate concentration
during the ongoing acid retention of chronic uremia [1001. Oh
does not argue that bone does not buffer substantial amounts of
hydrogen ions, but suggests only that if acute studies are extrap-
olated, the amount of bone necessary to buffer the cumulative
hydrogen ion retention would not last for more than a few years.
He also argues that the substantial depletion of bone carbonate
found in prior studies is not sufficient to account for more than a
small amount of hydrogen ion buffering on a daily basis over a
number of years. He agrees that bone is active in buffering acid
loads; however, he calculates that at some point a patient will run
out of the hydrogen ion buffering capacity of bone if no other
buffers are provided and if acid production remains constant.
In a previous Nephrology Forum, Gennari argued that because
dialysis patients are in overall neutral acid balance, albeit at a low
serum bicarbonate concentration, they do not rely on hydrogen
ion buffering by bone mineral [66]. He indicated that the serum
bicarbonate concentration falls between hemodialysis treatments
but that the lower the fall, the greater the flux of bicarbonate, or
the bicarbonate precursor acetate, into the patient during the
dialysis treatment. Patients had a mean predialysis bicarbonate
concentration of 17.8 2.2 mEq/liter (mean SD) and were
acidemic. Based on the in-vitro studies indicating that this degree
of hypobicarbonatemia is accompanied by an efflux of calcium
from and an influx of protons to bone, it appears that serum
[HC03] would fall further between dialysis treatments were it
not for the hydrogen ion buffering capacity of bone. Accordingly,
bone can be thought of as actively participating in the buffering of
the hydrogen ion retention during the interdialytic period. The
study by Lefebvre indicates that acidosis in dialysis patients is
clinically significant [69].
Synthesis
Overall, bone appears to lessen the magnitude of the fall in
serum [HC031 and blood pH during acute and chronic meta-
bolic acidosis. Initially the physicochemical processes of sodium
for hydrogen and potassium for hydrogen exchange occur on the
mineral surface in conjunction with dissolution of bone carbonate.
Cell-mediated osteoclastic resorption is then stimulated and
osteoblastic osteoid deposition is inhibited. The increased resorp-
tion releases the buffers carbonate and phosphate; the decrease in
bone formation blocks the hydrogen ion release that accompanies
bone mineral formation.
With adequate renal function, metabolic acidosis leads to an
increase in urinary calcium excretion. This increase is evidence for
breakdown of the bone mineral consequent to buffering of
hydrogen ions. Exchange of bone sodium and potassium for
hydrogen ions and release of carbonate all help mitigate the fall in
pH. As renal function deteriorates, urinary calcium excretion falls.
Bone carbonate is replaced by hydrogen phosphate adding base to
the extracellular fluid. Bone sodium and potassium are exchanged
18 for hydrogen ions. Osteoclastic bone resorption is accelerated,
and osteoblastic bone formation is curtailed. Hemodialysis pro-
vides an intermittent, and chronic ambulatory peritoneal dialysis a
relatively constant, supply of buffer to the extracellular fluid. If
this supply of buffer is not adequate to maintain a predialysis pH
and [HC03J in the normal range, however, the physicochemical
and cell-mediated effects of acidosis on the bone continue. How
do these effects of acidosis become apparent in the pathologic
findings observed in patients with uremic osteodystrophy?
High-turnover uremic osteodystrophy is accompanied by an
increased number of osteoclasts, which are stimulated to increase
bone resorption. Acidosis has been shown to stimulate osteoclas-
tic bone resorption both in vivo and in vitro and thus appears to
be one of several factors, including excess PTH, that stimulate
increased bone turnover during uremia. PTH and acidosis appear
to have an additive effect on calcium release in vitro and in viva.
During low-turnover uremic osteodystrophy, mineralization of
preformed osteoid decreases, and osteoblastic function decreases,
especially during aplastic disease. Again, these findings are con-
sistent with the in-vitro findings of decreased bone nodule min-
eralization and decreased osteoblastic collagen synthesis during
acidosis.
Therapeutic implications
The foregoing discussion suggests that acidosis should be
corrected prior to the institution of dialysis in patients with renal
insufficiency. Calcium carbonate has the advantage of not only
alkalinizing the patient [151, 1521, but also of being a nontoxic
phosphate binder [153, 1541. In patients who become hypercalce-
mic, sodium bicarbonate can be substituted for some of the
calcium carbonate if proper consideration is given to the addi-
tional sodium load. Enough base should be given to restore the
serum [HC03} to the normal range. There is little controversy in
the literature about the protection of bone mineral stores afforded
by correction of acidosis prior to the beginning of renal replace-
ment therapy.
With the initiation of either hemodialysis or peritoneal dialysis,
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one should try to maintain the predialysis serum [HC03]
concentration within the normal range. This can be accomplished
through the continued use of calcium carbonate and sodium
bicarbonate and by increasing the bicarbonate concentration in
the dialysis bath. However, administration of too much calcium,
with the resultant oversuppression of PTH, is associated with
aplastic uremic osteodystrophy [58]. One maneuver that possibly
can prevent hypercalcemia is lowering the concentration of the
calcium in the dialysis bath [155]. One well-designed clinical study
clearly indicates that correction of the acidosis moderates high-
turnover osteodystrophy and stimulates low-turnover osteodystro-
phy [69]. Perhaps with control of acidosis, PTH levels can be
maintained within the normal range without producing aplastic
osteodystrophy.
Substantial evidence suggests that bone participates in the
buffering of acute acidosis in patients with normal renal function.
With a reduction in renal excretory capacity, bone helps maintain
a life-sustaining pH and [HC03]. However, the evidence that
acidosis has a central role in the uremic osteodystrophy of dialysis
patients demands further study. Only through additional long-
term, controlled clinical studies will we be able to determine the
independent role of acidosis, and the effect of its correction, on
the bone disease observed in dialysis patients.
Questions and answers
DR. NICOLAOS E. MADIAS (Chief Division of Nephrology, New
England Medical Center, Boston, Massachusetts): Are there any
observations indicating that chronic administration of a low-
protein diet to patients with chronic renal insufficiency has
beneficial effects on their osteodystrophy?
DR. BUSHINSKY: To my knowledge the study that you suggest
has yet to be carried out. However, studies by Lemann et al
demonstrate that the provision of dietary protein increases cal-
cium excretion in normal humans [101], and the recent study by
Sebastian et a! indicates that neutralization of endogenous acid
production reduces calcium excretion, improves calcium balance,
reduces an index of bone breakdown, and increases an index of
bone formation [136]. In the study by Lefebvre and colleagues,
restoration of predialysis bicarbonate to normal curtailed the
progression of hyperparathyroidism in patients with high bone
turnover and stimulated bone turnover in patients with low rates
of bone formation [69]. In aggregate, these studies suggest that a
decrease in the magnitude of the acidemia, accomplished by
reducing the dietary protein intake, by oral administration of
bicarbonate, or by increasing dialysate bicarbonate concentration,
will have a beneficial influence on bone.
DR. MADIAs: You referred to effects of aluminum on bone cells
and the response of bone to acid. Given that most cases of what
is now referred to as adynamic bone disease are not aluminum
related, what is the pathogenetic role of metabolic acidosis and
the consequences of its correction in this type of bone disease?
DR. BUSHINSKY: As you indicate, low-turnover uremic osteodys-
trophy initially was clearly associated with aluminum accumula-
tion [50, 51]. Water utilized in preparing dialysate is now univer-
sally treated to remove aluminum, and most nephrologists make
every effort to decrease the amount of aluminum utilized as a
phosphate binder. These efforts have resulted in a marked de-
crease in aluminum-related osteomalacia. However, as you said,
we are now observing an increase in adynamic bone disease not
related to aluminum intoxication [58]. This form of uremic
osteodystrophy appears to be correlated with excessive suppres-
sion of PTH due to several interrelated factors. The administra-
tion of 1,25(OH)2D3 directly suppresses PTH. The absorption of
oral calcium, utilized as a phosphate binder, will be increased by
the 1,25(OH)2D3, resulting in hypercalcemia and PTH suppres-
sion. A relatively high level of calcium in dialysate, which has not
been reduced in conjunction with the increased oral calcium load,
will further suppress PTH. In spite of marked reductions in PTH
secretion engendered by these mechanisms, serum levels of PTH
remain above the normal range in many patients with adynamic
renal osteodystrophy [58].
How does acidosis fit into this picture? As I discussed, our
recent in-vitro studies indicate that metabolic acidosis inhibits
osteoblastic collagen synthesis [107, 119]. Receptors for PTH are
found only on the bone-forming osteoblasts and not the bone-
resorbing osteoclasts [12]. My speculation is that the osteoblasts
do not respond to the PTH because of the low-bicarbonate,
low-pH environment. Support for this hypothesis comes from the
paper by Lefebvre and colleagues, who found that in the subgroup
of patients with a normal-low bone formation rate, 7 of the 10 had
aplastic bone disease, and there was an increase in plasma
osteocalcin levels in those whose acidosis was corrected and no
change in osteocalcin in those who did not have their acidosis
corrected [69].
DR. MADIAs: Could you expand on the insensitivity of the
skeleton to PTH in uremic patients?
DR. BUSHINSKY: The calcemic response to the infusion of PTH
is smaller in hypocalemic patients with renal failure compared to
controls [156] and such hyporesponsiveness appears early in the
course of chronic renal failure [1571. The mechanism for this
apparent resistance is not clear and in all probability is multifac-
tonal. In bone culture, the serum of uremic patients appears to
inhibit PTH-mediated calcium release [158]. In humans [1591, but
not in dogs [1601, phosphate restriction has been reported to
improve the calcemic response to PTH. The administration of
1,25(OH)2D3 did not improve the calcemic response to PTH in
uremic dogs. However, parathyroidectomy 24 hours prior to PTH
infusion restored the calcemic response to normal [161]. This last
study suggests that in the presence of hyperparathyroidism, bone
cells might not be responsive to additional PTH.
Acidosis does not appear to inhibit the acute skeletal response
to PTH. While metabolic acidosis decreases osteoblastic collagen
synthesis and thus might be expected to decrease chronic bone
formation, acidosis increases osteoclastic activity and thus might
be expected to increase PTH-induced calcium release from bone
[107, 119]. Indeed, the combination of PTH and metabolic
acidosis increased calcium release from bone to a greater extent
than did either factor alone [109].
DR. JOHN T. HARRINGTON (Dean for Academic Affairs, Tufts
University School of Medicine, Boston, Massachusetts): You men-
tioned that bone pH was 4.5 or 5.0. How do you measure that? Is
it measured in vitro only? Can it be measured in vivo?
DR. BUSHINSKY: This extremely acidic pH is measured in the
microenvironment between the resorbing osteoclasts and the
bone. As you imply, this is a difficult measurement to make.
In-vitro studies both using microelectrodes [162] and pH-sensitive
fluorescent dyes [14] indicate that this space is indeed acidic. The
acidity not only promotes the dissolution of mineral but the
degradation of the organic matrix by cysteine proteinases [15]. To
my knowledge, the pH has not been measured in vivo.
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DR. HARRINGTON: Do we have direct measurements of bone
carbonate stores? Pellegrino did that a number of years ago. Are
there any better data available today? Assuming that there are, I
hope, what is the quantitative aspect of bone buffer available over
a 10- or 20-year period?
DR. BUSHINSKY: Pellegrino and coworkers [113, 1441 and Kaye
et al [145} found that uremia significantly reduced bone carbon-
ate. Bettice [87] and our own lab [88] independently determined
that acidosis decreased the carbonate content of bone. In addi-
tion, we found that the culture medium was in equilibrium with
the calcium and carbonate in bone [77] and that at a constant
medium pH the net calcium efflux from bone depends on bicar-
bonate concentration in the medium; the lower the bicarbonate
concentration, the greater the calcium efflux [81]. All these results
are consistent with the hypothesis that the carbonate in bone is a
proton buffer capable of maintaining the extracellular pH near the
normal range during acidosis.
As I mentioned, Oh argues that if you extrapolate from the
acute studies, there is simply not enough buffer available to
provide years and years of buffering during chronic acidosis [100].
There are certain assumptions in this argument. One is that our
diet, and hence our endogenous acid production, does not change
during uremia, which seems unlikely. A second assumption is that
uremia is a state of constant unremitting acidosis. As seen in the
patient presented today, there were times when the [HC03] was
16 mM, which will have a great impact on the skeleton, and times
when the [HC03] was 23 mM, which will have far less effect on
the bone. During periods of bicarbonate infusion, such as dialysis,
bone carbonate stores probably increase [66]. Thus the precise
arithmetic is difficult to do.
In answer to your question, do we have enough skeleton to
buffer 20 years of unremitting severe acidosis, probably not. Does
the skeleton contribute to maintenance of the normal extracellu-
lar pH during acidosis? Clearly, yes.
DR. MruAs: You mentioned that the osteoclast features a
vacuolar H ATPase and a Cl/HC03 exchanger in an arrange-
ment reminiscent of the polarized alpha intercalated cell of the
collecting duct. I assume that a Na/H exchanger, that is, the
NHE-1 isoform, also must be present, as it is a ubiquitous
transporter. Is there evidence for adaptation of any of these
transporters following chronic acid feeding or during chronic acid
exposure in your in-vitro culture system? Also, does inhibition of
the acidification function of the osteoclast, for example, by using
carbonic anhydrase inhibitors or inhibition of the transporters
mentioned, affect the ability of bone to buffer acid or the
bone-resorptive ability of the osteoclast?
DR. BusHINsKY: Blair and coworkers have described an H-
ATPase in osteoclasts that resembles the transporter found in
kidney in that it is sensitive to N-ethymaleimide and 7-chloro-4-
nitrobenz-2-oxa-1,3-diazole and insensitive to vanadate [16]. Teti
and coworkers have shown that lowering the medium pH stimu-
lates acid production by osteoclasts [163], and we have shown that
an acid medium pH produced by a decrease in [HC03] increases
osteoclastic 3-glucuronidase production [107, 119]. Inhibition of
osteoclastic Cl/HC03 exchanger [171 decreases osteoclastic
acidification [98] and bone resorption [164]. Patients with a
congenital absence of carbonic anhydrase, a disorder termed
osteopetrosis, have ongoing bone formation without bone resorp-
tion [165, 166]. Inhibition of cellular carbonic anhydrase decreases
bone resorption in vivo [167] and in vitro [75, 168].
DR. ANDREW KING (Division of Nephrology, New England Med-
ical Center): Some of your data showed a possible additive effect
of PTH and acidosis on bone turnover. If this effect does exist,
what is its proposed mechanism?
DR. BusFnNsKy: Both PTH and acidosis increase calcium re-
lease from bone [75]. Our recent preliminary data indicate that
the combination of PTH, 10'° M, and acidosis, pH 7.13, resulted
in greater calcium effiux from bone than either treatment alone
[109]. The combination of PTH and acidosis increased osteoclas-
tic f3-glucuronidase release and inhibited osteoblastic collagen
synthesis to a greater extent than either treatment alone. As I
mentioned early in my talk, the osteoblast has receptors for PTH
[12], and acidosis appears to directly inhibit osteoblastic activity
and stimulate osteoclastic activity [107, 119]. Whether the two
factors act independently on the bone cells or through a common
pathway is currently under investigation in our laboratory.
DR. KING: Frequently we are presented with patients who have
had progression to end-stage renal disease over a prolonged
period for unknown causes. Would there be any value in giving
these patients high doses of bicarbonate to reverse some of the
chronic effects of acidosis?
DR. BUSHINSKY: I believe that the data I have presented make
a strong case for the correction of chronic metabolic acidosis in
uremic patients. In patients with end-stage renal disease, we have
utilized calcium carbonate for this purpose; it not only provides
base, but the calcium is an effective phosphate binder. We aim for
restoration of bicarbonate to a nearly normal physiologic value of
24 mM. I would be hesistant to increase the [HC03] further, as
that would promote deposition of calcium and carbonate in
various tissue sites. Tissues most at risk—those that secrete
protons into a lumen, such as renal tubular and gastric parietal
cells—must lose a bicarbonate on the blood side, further increas-
ing the local alkalosis.
DR. ANDREW S. LEVEY (Division of Nephrology, New England
Medical Center): Could you discuss the role of the prevailing
hydrogen ion concentration versus the role of acid load in causing
calcium efflux from bone? To what extent do your experiments
distinguish between these two phenomena? Second, could you
comment on the status of the bones in children with type-Il RTA
in which the acid load is not altered but the concentration of
hydrogen ion is increased?
DR. BUSHINSKY: The prevailing hydrogen ion concentration in
patients with uremic acidosis is correlated with the extent to which
their daily hydrogen ion load is excreted. The extracellular fluid
pH falls in response to an acid load that is not fully excreted. If the
pH and [HC03] are low, the patient is acidemic, indicating that
acid intake is greater than acid excretion. I am not aware of
physiologic mechanisms, other than the prevailing proton and
bicarbonate concentration, that determine the extent to which an
acid load is excreted. As far as we know, the bone responds to pH
and [HCO3J; it has no other regulatory signals to determine acid
balance. Proton buffers, especially those in bone, help to mitigate
the fall in pH caused by unexcreted acid loads. When we culture
bone, we fix the [HCO3], which at a given PCO2 will determine
the PH; the [HC03] and the pH determine the magnitude of the
calcium release.
With respect to renal tubular acidosis, as I indicated, McSherry
and Morris observed that in children with classic renal tubular
acidosis, the administration of bicarbonate markedly increased
growth rate [138]. Brenner et al found that in patients with type-I!
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RTA, the majority of children had rickets and the majority of
adults had osteopenia [1411. In those with type-I RTA, most had
nephrocalcinosis and/or nephrolithiasis. Thus there appears to be
evidence of abnormal calcium metabolism in both type-I and
type-Il RTA.
DR. MADIAs: Could you comment on the difference between
metabolic and respiratory acidosis in terms of calcium effiux?
What do you think is the sensor that determines the different
response to the two disorders?
DR. BUSHINSKY: There is a striking difference between the
effects of metabolic and respiratory acidosis on net calcium efflux
from cultured bone [65, 74, 81, 89, 91, 106, 108, 117, 119]. During
acute incubation, there is a far greater net efflux of calcium during
metabolic, compared to respiratory, acidosis, and bone buffers the
increase in hydrogen ions during metabolic, but not respiratory,
acidosis [891. With respiratory acidosis, there is not only less
unidirectional calcium efflux from bone, but there appears to be
deposition of medium calcium on the bone surface [117]. The
bone surface contains abundant sodium and potassium in relation
to calcium [911. Metabolic acidosis not only causes more calcium
effiux, but a greater loss of bone sodium and potassium compared
with respiratory acidosis [91]. Metabolic, but not respiratory,
acidosis decreases bone carbonate [88]. We have shown that over
this short period of time, acidosis affects the physicochemical
driving forces for mineral formation and dissolution [75] and that
the medium is in equilibrium with the carbonated apatite of bone
[77]. Under isohydric conditions, calcium effiux from bone is
governed by the medium [HCO3I as the major component of
total carbon dioxide [81]. With metabolic acidosis, the low
[HC03] and the low PCO2 decrease the driving force for
carbonate apatite formation and thus favor physicochemical bone
dissolution [81]. During respiratory acidosis the increased PCO2
and the slightly elevated [HC03] increase the driving force for
carbonate apatite formation and favor the deposition of carbonate
apatite [81].
During incubations longer than 48 hours, there is net cell-
mediated calcium efflux from bone during metabolic, but not
respiratory, acidosis [106]. Metabolic acidosis decreases the min-
eralization of cultured osteoblasts to a greater extent than respi-
ratory acidosis [108]. This observation is consistent with our
current thinking about cell-mediated bone resorption. As I said
earlier, the osteoclasts form a tight seal with the bone and secrete
hydrogen ions into this microenvironment [14—16]. For each
hydrogen ion secreted, a bicarbonate must leave the osteoclast. A
low medium [HCO3] facilitates the exchange of intracellular
HC03 for extracellular C1 and leads to an increase in hydrogen
ion availability and secretion. The lowered pH in the microenvi-
ronment would increase bone resorption. An elevated partial
pressure of carbon dioxide, as in respiratory acidosis, would not be
expected to stimulate the CL/HC03 exchanger and would not
be expected to stimulate bone resorption. We have recently shown
that metabolic acidosis stimulates osteoclastic f3-glucuronidase
release and inhibits osteoblastic collagen synthesis; respiratory
acidosis does not appear to appreciably affect the function of
either cell type [119].
DR. MADIAS: Metabolic acidosis produces a more pronounced
adaptation of the vacuolar H-ATPase in the intercalated cells of
the collecting duct than does respiratory acidosis [169].
DR. BUSHINSKY: As a nephrologist, I think of an osteoclast as a
misplaced intercalated cell.
DR. HARRINGT0N: Have you studied respiratory alkalosis, that
is, a low-bicarbonate, high-pH situation, in cultured bone studies?
DR. BUSHINSKY: To date we have concentrated on acidosis, both
metabolic and respiratory. A potential problem in studying alka-
losis is that calcium is less soluble as the pH rises and may
precipitate in the culture medium. In addition, utilizing the
scanning ion microprobe in conjunction with the stable isotope
we have shown that bone formation in this system does not
appear to be physiologic [94].
DR. HARRINGTON: Your proposal for restoring bicarbonate to
normal in pre-dialysis and dialysis patients is an interesting
hypothesis. Do any studies show a real difference in clinical
outcome in patients who have been treated in a bicarbonate-rich
fashion?
DR. BUSHINSKY: The study by Lefebvre that we discussed
demonstrated that the correction of acidosis decreased the pro-
gression of hyperparathyroidism in patients with high bone turn-
over and stimulated bone turnover in patients with low bone
formation [69]. I am not aware of any other data.
DR. SERGE LEMAY (Renal Fellow, Division of Nephrology, New
England Medical Center): You showed that there is calcium efflux
from bone in acidosis and that the ratio of sodium and potassium
to calcium is high. Would it be unreasonable to speculate that
bone resorption could cause hyperkalemia in patients with renal
failure who suffer from immobilization or secondary hyperpara-
thyroidism?
DR. BUSHJNSKY: We have shown that metabolic, but not respi-
ratory, acidosis induces a greater release of bone-surface sodium
and potassium compared with calcium [91]. Others have shown
that metabolic, to a greater extent than respiratory, acidosis is
associated with an increase in serum potassium [170]. Thus, with
respect to potassium, there is a parallel systemic and osseous
response to acidosis. Perhaps, and this is only speculation, some of
the additional serum potassium originates from bone. The extra-
cellular sodium concentration is approximately 145 mM; an influx
of sodium resulting in an increase of even 1—2 mM would be
difficult to detect clinically. Your speculation that immobilization
or hyperparathyroidism might cause hyperkalemia during renal
failure is not unreasonable but must be tested.
DR. MADJAs: Would you review the relationship between
acidosis and vitamin D metabolism?
DR. BUSHINSKY: In humans, acidosis increases urinary calcium
and phosphorus. However, there appears to be no change in the
levels of PTH or 1,25(OH)2D3 [123, 124], and PTH infusion leads
to an appropriate increase in 1,25(OH)2D3 [1351. The usual
physiologic response to hypercalciuria is a fall in serum calcium
that leads to an increase in circulating PTH and 1,25(OH)2D3 [21.
Intestinal calcium absorption is stimulated, resulting in restora-
tion of serum calcium toward normal. Perhaps the acid-induced
hypercalciuria does not result in this cascade of events, because as
blood pH falls, there is a displacement of calcium from albumin
that leads to an increase in biologically active ionized calcium
[128]. An increase in ionized calcium inhibits PTH secretion and
independently inhibits the conversion of 25(OH)D3 to 1,25
(OH)2D3 [2]. In the presence of acidosis-induced hypercalciuria,
the lack of an increase in intestinal calcium absorption indicates
that the additional urinary calcium must be coming from bone
[631.
DR. MARK PARKER (Renal Fellow, Division of Nephrology, New
England Medical Center): I'd like to follow up on Dr. Madias' first
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question regarding adynamic bone disease and your response
about acidosis in low-turnover disease. You noted that osteoblas-
tic activity is inhibited in chronic metabolic acidosis, consistent
with the pathogenesis of the adynamic lesion. However, you also
noted that chronic metabolic acidosis stimulates osteoclastic
activity. In fact, you pointed out that the latter finding is consistent
with high-turnover disease. How do you reconcile the activity of
the osteoclast in acidosis with what happens in adynamic disease?
DR. BUSHINSKY: There are many influences on the skeleton
during renal insufficiency and renal failure. There are alterations
in relevant hormones such as PTH and 1,25(OH)2D3, and ions
such as calcium, phosphorus, and magnesium in addition to the
variations in hydrogen ion, which has been the focus of today's
Forum. How each of the ions and hormones fit into the complex
puzzle of uremic osteodystrophy is slowly unfolding. We don't
know why some patients develop the high-turnover disorder and
other patients, with similar biochemical parameters, develop
low-turnover disease. Nor do we know why the correction of
acidosis appears to improve both high-turnover and low-turnover
uremic osteodystrophy [69].
In vitro we can examine the influence of a single ionic or
hormonal perturbation on the bone mineral, on a subset of bone
cells, or on overall bone homeostasis. The knowledge gained in
vitro can be utilized to help us better understand our observations
in vivo. With further knowledge, gained through research, we
someday might be able to more intelligently answer your question.
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